NASDAQ:ALLK - Allakos Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allakos Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $44.68 -0.09 (-0.20 %) (As of 03/31/2020 12:08 PM ET) Add Compare Today's Range$43.23Now: $44.68▼$46.3850-Day Range$44.77MA: $60.25▼$69.9052-Week Range$30.32Now: $44.68▼$139.99Volume73,784 shsAverage Volume436,856 shsMarket Capitalization$2.18 billionP/E RatioN/ADividend YieldN/ABeta-0.39 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.allakos.com/ Phone650-597-5002Debt Debt-to-Equity RatioN/A Current Ratio38.27 Quick Ratio38.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book4.38Profitability EPS (Most Recent Fiscal Year)($1.89) Net Income$-85,370,000.00 Net MarginsN/A Return on Equity-25.67% Return on Assets-24.28%Miscellaneous Employees62 Outstanding Shares48,710,000Market Cap$2.18 billion Next Earnings Date5/13/2020 (Estimated) OptionableNot Optionable Receive ALLK News and Ratings via Email Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALLK Rates by TradingView Allakos (NASDAQ:ALLK) Frequently Asked Questions How has Allakos' stock been impacted by COVID-19 (Coronavirus)? Allakos' stock was trading at $58.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALLK shares have decreased by 23.4% and is now trading at $44.68. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Allakos? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allakos. When is Allakos' next earnings date? Allakos is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Allakos. How were Allakos' earnings last quarter? Allakos Inc (NASDAQ:ALLK) posted its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.03. View Allakos' earnings history. What price target have analysts set for ALLK? 3 brokers have issued 1 year price targets for Allakos' stock. Their forecasts range from $36.00 to $94.00. On average, they anticipate Allakos' stock price to reach $65.00 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View analysts' price targets for Allakos. What are Wall Street analysts saying about Allakos stock? Here are some recent quotes from research analysts about Allakos stock: 1. According to Zacks Investment Research, "Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. " (2/28/2020) 2. William Blair analysts commented, "Wenzel has extensive experience conducting clinical trials in asthma patients, including as lead author in the Phase II trials of Dupixent (Wenzel et al., 2016) and co-author in the Phase III trials. For additional background on PRS-060 and FeNO biology , see our recent note, at ERS With Promising Clinical Profile." (8/9/2019) Has Allakos been receiving favorable news coverage? News headlines about ALLK stock have been trending very positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allakos earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAllakos. Are investors shorting Allakos? Allakos saw a increase in short interest in February. As of February 28th, there was short interest totaling 7,990,000 shares, an increase of 7.5% from the February 13th total of 7,430,000 shares. Based on an average daily volume of 409,800 shares, the short-interest ratio is presently 19.5 days. Currently, 34.1% of the shares of the stock are sold short. View Allakos' Current Options Chain. Who are some of Allakos' key competitors? Some companies that are related to Allakos include Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Sarepta Therapeutics (SRPT), Mylan (MYL), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA) and Amarin (AMRN). What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include Advanced Micro Devices (AMD), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Tesla (TSLA), AbbVie (ABBV), General Motors (GM), Pfizer (PFE), Exxon Mobil (XOM) and Agios Pharmaceuticals (AGIO). Who are Allakos' key executives? Allakos' management team includes the following people: Dr. Robert Alexander, Pres, CEO & Director (Age 49)Dr. Adam L. Tomasi, CFO, COO & Sec. (Age 49)Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 60)Dr. Ruby Casareno Ph.D., VP of Technical OperationsMr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 56) When did Allakos IPO? (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. What is Allakos' stock symbol? Allakos trades on the NASDAQ under the ticker symbol "ALLK." How do I buy shares of Allakos? Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $44.68. How big of a company is Allakos? Allakos has a market capitalization of $2.18 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe. View additional information about Allakos. What is Allakos' official website? The official website for Allakos is http://www.allakos.com/. How can I contact Allakos? Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected] MarketBeat Community Rating for Allakos (NASDAQ ALLK)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 138 (Vote Outperform)Underperform Votes: 169 (Vote Underperform)Total Votes: 307MarketBeat's community ratings are surveys of what our community members think about Allakos and other stocks. Vote "Outperform" if you believe ALLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: What are popular green investing opportunities?
